A Multicenter, Single Arm, Open Label, Phase IV Study to Evaluate Safety and to Describe the Cumulative Incidence of Major Cardiovascular Events of Ticagrelor in Taiwanese Patients With Non ST-segment Elevation Myocardial Infarction
Phase of Trial: Phase IV
Latest Information Update: 15 Mar 2017
At a glance
- Drugs Ticagrelor (Primary)
- Indications Myocardial infarction
- Focus Adverse reactions
- Sponsors AstraZeneca
- 10 Mar 2017 Status changed from active, no longer recruiting to completed.
- 18 Apr 2016 Planned End Date changed from 1 Mar 2017 to 1 Feb 2017.
- 18 Apr 2016 Planned primary completion date changed from 1 Mar 2017 to 1 Feb 2017.